MCK Quote, Financials, Valuation and Earnings

Cardinal Health, Inc. has a net margin of 1.13% compared to McKesson Corp.'s net margin of 0.71%. McKesson Corp.'s return on equity of -- beat Cardinal Health, Inc.'s return on equity of --.

McKesson Corp. has a consensus price target of $939.33, signalling upside risk potential of 13.76%. On the other hand Cardinal Health, Inc. has an analysts' consensus of $216.60 which suggests that it could grow by 4.45%. Given that McKesson Corp. has higher upside potential than Cardinal Health, Inc., analysts believe McKesson Corp. is more attractive than Cardinal Health, Inc..

McKesson Corp. has a beta of 0.382, which suggesting that the stock is 61.811% less volatile than S&P 500. In comparison Cardinal Health, Inc. has a beta of 0.626, suggesting its less volatile than the S&P 500 by 37.423%.

McKesson Corp. has a quarterly dividend of $0.82 per share corresponding to a yield of 0.37%. Cardinal Health, Inc. offers a yield of 0.98% to investors and pays a quarterly dividend of $0.51 per share. McKesson Corp. pays 10.69% of its earnings as a dividend. Cardinal Health, Inc. pays out 31.43% of its earnings as a dividend. Both of these payout ratios are sufficient to cover dividend payouts with earnings for the foreseeable future.

McKesson Corp. quarterly revenues are $103.2B, which are larger than Cardinal Health, Inc. quarterly revenues of $64B. McKesson Corp.'s net income of $1.2B is higher than Cardinal Health, Inc.'s net income of $454M. Notably, McKesson Corp.'s price-to-earnings ratio is 25.71x while Cardinal Health, Inc.'s PE ratio is 31.34x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for McKesson Corp. is 0.27x versus 0.21x for Cardinal Health, Inc.. Usually stocks with elevated PS ratios are considered overvalued.

Cencora, Inc. has a net margin of 1.13% compared to McKesson Corp.'s net margin of -0.4%. McKesson Corp.'s return on equity of -- beat Cencora, Inc.'s return on equity of 124.72%.

McKesson Corp. has a consensus price target of $939.33, signalling upside risk potential of 13.76%. On the other hand Cencora, Inc. has an analysts' consensus of $387.93 which suggests that it could grow by 14.11%. Given that Cencora, Inc. has higher upside potential than McKesson Corp., analysts believe Cencora, Inc. is more attractive than McKesson Corp..

McKesson Corp. has a beta of 0.382, which suggesting that the stock is 61.811% less volatile than S&P 500. In comparison Cencora, Inc. has a beta of 0.632, suggesting its less volatile than the S&P 500 by 36.802%.

McKesson Corp. has a quarterly dividend of $0.82 per share corresponding to a yield of 0.37%. Cencora, Inc. offers a yield of 0.66% to investors and pays a quarterly dividend of $0.60 per share. McKesson Corp. pays 10.69% of its earnings as a dividend. Cencora, Inc. pays out 27.63% of its earnings as a dividend. Both of these payout ratios are sufficient to cover dividend payouts with earnings for the foreseeable future.

McKesson Corp. quarterly revenues are $103.2B, which are larger than Cencora, Inc. quarterly revenues of $83.7B. McKesson Corp.'s net income of $1.2B is higher than Cencora, Inc.'s net income of -$333.1M. Notably, McKesson Corp.'s price-to-earnings ratio is 25.71x while Cencora, Inc.'s PE ratio is 42.76x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for McKesson Corp. is 0.27x versus 0.21x for Cencora, Inc.. Usually stocks with elevated PS ratios are considered overvalued.

Globus Medical, Inc. has a net margin of 1.13% compared to McKesson Corp.'s net margin of 15.47%. McKesson Corp.'s return on equity of -- beat Globus Medical, Inc.'s return on equity of 10.08%.

McKesson Corp. has a consensus price target of $939.33, signalling upside risk potential of 13.76%. On the other hand Globus Medical, Inc. has an analysts' consensus of $98.73 which suggests that it could grow by 11.65%. Given that McKesson Corp. has higher upside potential than Globus Medical, Inc., analysts believe McKesson Corp. is more attractive than Globus Medical, Inc..

McKesson Corp. has a beta of 0.382, which suggesting that the stock is 61.811% less volatile than S&P 500. In comparison Globus Medical, Inc. has a beta of 1.070, suggesting its more volatile than the S&P 500 by 7.046%.

McKesson Corp. has a quarterly dividend of $0.82 per share corresponding to a yield of 0.37%. Globus Medical, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. McKesson Corp. pays 10.69% of its earnings as a dividend. Globus Medical, Inc. pays out -- of its earnings as a dividend. McKesson Corp.'s payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

McKesson Corp. quarterly revenues are $103.2B, which are larger than Globus Medical, Inc. quarterly revenues of $769M. McKesson Corp.'s net income of $1.2B is higher than Globus Medical, Inc.'s net income of $119M. Notably, McKesson Corp.'s price-to-earnings ratio is 25.71x while Globus Medical, Inc.'s PE ratio is 28.58x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for McKesson Corp. is 0.27x versus 4.40x for Globus Medical, Inc.. Usually stocks with elevated PS ratios are considered overvalued.

Pineapple, Inc. has a net margin of 1.13% compared to McKesson Corp.'s net margin of -184.62%. McKesson Corp.'s return on equity of -- beat Pineapple, Inc.'s return on equity of --.

McKesson Corp. has a consensus price target of $939.33, signalling upside risk potential of 13.76%. On the other hand Pineapple, Inc. has an analysts' consensus of -- which suggests that it could fall by --. Given that McKesson Corp. has higher upside potential than Pineapple, Inc., analysts believe McKesson Corp. is more attractive than Pineapple, Inc..

McKesson Corp. has a beta of 0.382, which suggesting that the stock is 61.811% less volatile than S&P 500. In comparison Pineapple, Inc. has a beta of 40.248, suggesting its more volatile than the S&P 500 by 3924.762%.

McKesson Corp. has a quarterly dividend of $0.82 per share corresponding to a yield of 0.37%. Pineapple, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. McKesson Corp. pays 10.69% of its earnings as a dividend. Pineapple, Inc. pays out -- of its earnings as a dividend. McKesson Corp.'s payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

McKesson Corp. quarterly revenues are $103.2B, which are larger than Pineapple, Inc. quarterly revenues of $1.3K. McKesson Corp.'s net income of $1.2B is higher than Pineapple, Inc.'s net income of -$2.4K. Notably, McKesson Corp.'s price-to-earnings ratio is 25.71x while Pineapple, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for McKesson Corp. is 0.27x versus 85.85x for Pineapple, Inc.. Usually stocks with elevated PS ratios are considered overvalued.